Table 4.
Comparison of studies on the prevalence of metabolic syndrome in the general adult population and adults with thyroid disorders
| Author (year) | Country | Population | Prevalence of metabolic syndrome | Reference |
|---|---|---|---|---|
| General Population | ||||
| Noubiap (2022) | Worldwide | N = 28,193,768 adults from 1,129 prevalence studies | 12.5% by NCEP/ATP III criteria 28.2% by IDF criteria 29.1% by NCEP/ATP III-AHA/NHLBI criteria 31.4% by Joint Interim Statement (JIS) criteria |
13 |
| Punzalan (2004) | Philippines | N = 4541 (adults ≥20 years) | 14.2% by NCEP/ATP III criteria 19.3% by International Atherosclerosis (IAS) criteria |
12 |
| Morales (2008) | Philippines | N = 4753 (adults ≥20 years) | 11.9% by NCEP/ATP III criteria 14.5% by IDF criteria 18.6% by NCEP/ATP III-AHA/NHLBI criteria |
14 |
| Mata (2017) | Philippines | N = 1367 | 51.0% by NCEP/ATP III-AHA/NHLBI criteria 29.6% among normal BMI 18.5 – 22.9 kg/m2 38.9% among overweight BMI 23.0 – 24.9 kg/m2 56.9% among obese class I BMI 25.0 – 29.9 kg/m2 62.4% among obese class II BMI ≥ 30 kg/m2 |
15 |
| Patients with thyroid dysfunction | ||||
| Chiu (2023) | Philippines | N = 105 | 36.19% among patients with hypothyroidism using Harmonizing definition (n = 38) 32.43% in men (n = 12) and 38.24% in women |
16 |
| Ogbera (2012) | Nigeria | N = 112 | 28.0% by NCEP/ATP III-AHA/NHLBI criteria 40.0% among patients with hypothyroidism by NCEP/ATP III-AHA/NHLBI criteria (n = 10) 24.0% among patients with hyperthyroidism by NCEP/ATP III-AHA/NHLBI criteria (n = 90) 42.0% among patients with non-toxic goiter by NCEP/ATP III-AHA/NHLBI criteria (n = 12) |
17 |
| Khare (2017) | Southern India | N = 154 | 53.24% among patients with hypothyroidism by NCEP/ATP III criteria (n = 82) | 18 |
| Bermudez (2018) | Venezuela | N = 391 | 56.8% among patients with subclinical hypothyroidism by IDF criteria (n = 41) No data available among euthyroid patients |
19 |